GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol.

ABSTRACT:

Introduction

Chronic pelvic pain (CPP) affects more than 1 million UK women with associated healthcare costs of £158 million annually. Current evidence supporting interventions when no underlying pathology is identified is very limited and treatment is frequently inadequate. Gabapentin (a GABA analogue) is efficacious and often well tolerated in other chronic pain conditions. We have completed a successful pilot randomised controlled trial Gabapentin for Pelvic Pain 1 (GaPP1) and here describe the protocol for our definitive multicentre trial to assess the efficacy of gabapentin in the management of CPP in women Gabapentin for Pelvic Pain 2 (GaPP2).

Methods and analysis

We plan to perform a double-blind placebo-controlled randomised multicentre clinical trial, recruiting 300

SUBMITTER: Vincent K 

PROVIDER: S-EPMC5879736 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature